MedTrace Logo

A Study in Adults With Type 1 Diabetes

NCT01421147 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 536

Last updated 2014-10-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus when taken once daily in combination with insulin lispro before meals three times a day.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

DRUG

LY2963016

Administered subcutaneously

DRUG

Lantus

Administered subcutaneously

DRUG

Insulin Lispro

Administered subcutaneously

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-08-31
Completion
2013-04-30

Countries

  • United States
  • Belgium
  • Germany
  • Greece
  • Hungary
  • Japan
  • Mexico
  • Poland
  • Romania

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01421147 on ClinicalTrials.gov